• Report Adverse Event or Product Quality Complaint
  • Global Site
AstraZeneca Medical Information
  • Prescribing Information
  • Resources
    • Congress Library
    • Our Pipeline
    • AZ Clinical Trials
    • Externally Sponsored Scientific Research
  • Connect
    • Send MIR
    • Give Feedback

Search Medical Information

European Society of Hypertension (ESH) – 34th European Meeting on Hypertension and Cardiovascular Protection - 2025

May 23 - 26, 2025

  1. Hypertension

pdf

Baseline characteristics of patients in BaxHTN: a phase 3 trial of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension

pdf

Graphical abstract of Baseline characteristics of patients in BaxHTN: a phase 3 trial of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension

pdf

Epidemiology and clinical burden of disease among uncontrolled and treatment-resistant hypertension patients: A systematic literature review

pdf

Graphical abstract of Epidemiology and clinical burden of disease among uncontrolled and treatment-resistant hypertension patients: A systematic literature review

pdf

Spironolactone in the treatment of uncontrolled and treatment-resistant hypertension: A systematic literature review

pdf

Graphical abstract of Spironolactone in the treatment of uncontrolled and treatment-resistant hypertension: A systematic literature review

html

High rates of mineralocorticoid receptor antagonist discontinuation in patients with hypertension: Insights from the EnligHTN study

pdf

Inadequately controlled hypertension – patient profiles in Germany and Spain: Insights from the EnligHTN study

pdf

Graphical abstract of Inadequately controlled hypertension – patient profiles in Germany and Spain: Insights from the EnligHTN study

html

Medication profiles in patients with inadequately controlled hypertension: Insights from the EnligHTN study

Need Help?

Contact Us

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

AstraZeneca Logo

This platform is provided as service to healthcare professionals by AstraZeneca Philippines, for medical educational purposes only.

©2024 AstraZeneca. All rights reserved.

PH-10554.

Last Updated 5/24

Contact Us

About Us

AstraZeneca.com

Survey Feedback

Privacy Notice

Legal Notice

Cookie Notice

Global Site

Report Adverse Event or Product Quality Complaint

Privacy NoticeLegal NoticeCookie Notice

Welcome to AstraZeneca Philippines Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the Philippines, for medical educational purposes only. AstraZeneca does not engage in the promotion of unregistered products or unapproved indications. The dissemination of this information may be subject to different medical and regulatory requirements in other countries

Are you a healthcare professional practicing in the Philippines?

No